Jai-Hyuck Han1, Young Seok Park2, Won Hyoung Lee3, Sung-Soo Koong1,3,4, Kyung-Soo Min1, Mou-Seop Lee1, Young-Gyu Kim1, Dong-Ho Kim1, Kyung-Sil Yi4, Sang-Hoon Cha4. 1. Department of Neurosurgery, Chungbuk National University Hospital, Chungbuk National University, College of Medicine, 776, Gaesindong, Sewongu, Cheongju, Republic of Korea. 2. Department of Neurosurgery, Chungbuk National University Hospital, Chungbuk National University, College of Medicine, 776, Gaesindong, Sewongu, Cheongju, Republic of Korea. youngseokparkmd@gmail.com. 3. Department of Nuclear Medicine, Chungbuk National University Hospital, Chungbuk National University, College of Medicine, Cheongju, Republic of Korea. 4. Department of Radiology, Chungbuk National University Hospital, Chungbuk National University, College of Medicine, Cheongju, Republic of Korea.
Abstract
BACKGROUND AND PURPOSE: Cerebral angiography (CA) is the gold standard for moyamoya disease (MMD) staging and diagnosis, but CA findings are not well correlated with clinical symptoms. The purpose of this study was to establish novel cerebral-perfusion-based staging for MMD that is well correlated with clinical symptoms. MATERIALS AND METHODS: From 2010 to 2015, regional cerebrovascular reserve (rCVR) was examined by single-photon emission computed tomography (SPECT) using NeuroGam® (Segamicorp, Houston, TX, USA) in 30 patients (17 women, 13 men; 60 hemispheres; mean 42.0 years old [range 5-60 years old]) with MMD, which was diagnosed by CA and magnetic resonance angiography (MRA). Brain CT or brain magnetic resonance imaging (MRI) was used to evaluate neurological conditions such as transient ischemic attack (TIA), cerebral hemorrhage, and cerebral infarction. A novel staging system for MMD was developed by combining findings from CA, MRI, and SPECT with NeuroGam®. RESULTS: Our novel staging system was strongly associated with clinical symptoms. Twenty-two hemispheres out of 60 were categorized as stage I, 24 hemispheres were categorized as stage II, and 14 hemispheres were categorized as stage III. Hemispheres with higher scores exhibited a higher incidence of clinical symptoms. These findings indicate that cerebral-perfusion-based staging is predictive of MMD clinical symptoms. CONCLUSION: Perfusion-based SPECT staging correlates well with clinical symptoms and may be a reliable alternative to the Suzuki staging by CA.
BACKGROUND AND PURPOSE: Cerebral angiography (CA) is the gold standard for moyamoya disease (MMD) staging and diagnosis, but CA findings are not well correlated with clinical symptoms. The purpose of this study was to establish novel cerebral-perfusion-based staging for MMD that is well correlated with clinical symptoms. MATERIALS AND METHODS: From 2010 to 2015, regional cerebrovascular reserve (rCVR) was examined by single-photon emission computed tomography (SPECT) using NeuroGam® (Segamicorp, Houston, TX, USA) in 30 patients (17 women, 13 men; 60 hemispheres; mean 42.0 years old [range 5-60 years old]) with MMD, which was diagnosed by CA and magnetic resonance angiography (MRA). Brain CT or brain magnetic resonance imaging (MRI) was used to evaluate neurological conditions such as transient ischemic attack (TIA), cerebral hemorrhage, and cerebral infarction. A novel staging system for MMD was developed by combining findings from CA, MRI, and SPECT with NeuroGam®. RESULTS: Our novel staging system was strongly associated with clinical symptoms. Twenty-two hemispheres out of 60 were categorized as stage I, 24 hemispheres were categorized as stage II, and 14 hemispheres were categorized as stage III. Hemispheres with higher scores exhibited a higher incidence of clinical symptoms. These findings indicate that cerebral-perfusion-based staging is predictive of MMD clinical symptoms. CONCLUSION: Perfusion-based SPECT staging correlates well with clinical symptoms and may be a reliable alternative to the Suzuki staging by CA.
Authors: C Heyn; J Poublanc; A Crawley; D Mandell; J S Han; M Tymianski; K terBrugge; J A Fisher; D J Mikulis Journal: AJNR Am J Neuroradiol Date: 2010-01-14 Impact factor: 3.825
Authors: Yoo Sung Song; So Won Oh; Yu Keong Kim; Seung-Ki Kim; Kyu-Chang Wang; Dong Soo Lee Journal: Ann Nucl Med Date: 2011-10-28 Impact factor: 2.668
Authors: T C Hill; B L Holman; R Lovett; D H O'Leary; D Front; P Magistretti; R E Zimmerman; S Moore; M E Clouse; J L Wu; T H Lin; R M Baldwin Journal: J Nucl Med Date: 1982-03 Impact factor: 10.057
Authors: R L Grubb; C P Derdeyn; S M Fritsch; D A Carpenter; K D Yundt; T O Videen; E L Spitznagel; W J Powers Journal: JAMA Date: 1998 Sep 23-30 Impact factor: 56.272